HomeStudy cornerDonanemab
donanemab

Donanemab

Donanemab - A Promising Treatment for Alzheimer's Disease

Donanemab (Kisunla): A Promising Treatment for Alzheimer's Disease

Donanemab Image

Donanemab, also known by its brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer’s disease. It is designed to slow down the decline in memory, thinking, and daily functioning associated with Alzheimer’s. Here are some key points about Donanemab:

Mechanism of Action

The monoclonal antibody Donanemab targets amyloid plaques in the brain, which are thought to contribute to Alzheimer’s symptoms. By helping the body remove these plaques, it slows the progression of the disease.

FDA Approval

Donanemab received FDA approval on July 2, 2024, as a treatment for adults with early symptomatic Alzheimer’s disease (including those with mild cognitive impairment) and confirmed amyloid pathology.

Clinical Trial Results

In the TRAILBLAZER-ALZ 2 clinical trial, it is significantly slowed Alzheimer’s disease progression by more than 20% at 76 weeks. Patients in earlier stages of the disease showed the most significant improvements.

Common Side Effects

Headache and swelling in brain areas (with or without small spots of bleeding) occurred in at least 10% of patients.

Serious Side Effects

Serious allergic reactions (swelling of face, difficulty breathing, hives) and infusion-related reactions (sweating, headache, nausea, chest pain) may occur.

Donanemab represents a promising advancement in Alzheimer’s treatment, and its approval provides hope for patients and their families.

You May Also Like

Amoxicillin Quiz Amoxicillin Quiz Time Remaining: 10:00 Email: 1. What is the primary use of amoxicillin? Treat viral infections Treat...
Amoxicillin Amoxicillin: An Overview What is Amoxicillin? Amoxicillin is a penicillin antibiotic that is used to treat a wide variety...
Introduction Parkinson’s disease, a chronic and progressive movement disorder, affects millions worldwide. First described by James Parkinson in 1817, its...

Discover more from PETC

Subscribe now to keep reading and get access to the full archive.

Continue reading

Open chat
1
Scan the code
Hello
Please let me know how Can we help you?